Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Physician's Weekly16h
Peptide-1 Agonist Relieves IBS Pain but Raises Side Effects
The following is a summary of “Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a ...
Medical Marketing & Media7h
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
BioSpace5d
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
Fierce Biotech9d
AbbVie pays Gubra $350M to make late play for obesity space
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...
BioPharma Dive8h
Roche broadens obesity drug plans with $1.65B Zealand deal
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche is stepping into the hot weight-loss drug market currently dominated by Novo Nordisk (NVO) and Eli Lilly (LLY). The ...